<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03961191</url>
  </required_header>
  <id_info>
    <org_study_id>METHY1</org_study_id>
    <nct_id>NCT03961191</nct_id>
  </id_info>
  <brief_title>DNA Methylation for Screening Uterine Cervical Lesions: A Case-control Study</brief_title>
  <official_title>Utilization of DNA Methylation in the Screening of Uterine Cervical Lesions: A Case-control Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lei Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the testing of DNA methylation, high-risk
      HPV subtypes, and cytology with the definite histological results in a case-control study, so
      as to determine the accuracy of DNA methylation in the screening of uterine cervical lesions.

      This study will include 300 patients with definite histological results, with 100 of cervical
      inflammation or low grade squamous intraepithelial lesions (LSIL), 100 of high grade squamous
      intraepithelial lesions (HSIL), and 100 of uterine cervical cancer. All the cervical
      specimens of cytology collected in the clinical settings will be utilized for the testing of
      DNA methylation, high-risk HPV subtypes and thin prep liquid-based cytology test (TCT). The
      sensitivity, specificity, positive predictive value and negative predictive value were
      calculated based on the known histological results. The differences of DNA methylation with
      high-risk human papillomavirus (HPV) and TCT will also be analyzed.

      The testing of DNA methylation will be performed with the methylation-specific polymerase
      chain reaction (PCR). The TCT and HPV testing will be performed with the Roche kits.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 22, 2019</start_date>
  <completion_date type="Anticipated">May 22, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 22, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of DNA methylation</measure>
    <time_frame>1 years</time_frame>
    <description>Sensitivity of DNA methylation compared with histological results for the differentiation of cervical cancer and HSIL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity of DNA methylation</measure>
    <time_frame>1 years</time_frame>
    <description>Specificity of DNA methylation compared with histological results for the differentiation of cervical cancer and HSIL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive predictive value of DNA methylation</measure>
    <time_frame>1 year</time_frame>
    <description>Positive predictive value of DNA methylation compared with histological results for the differentiation of cervical cancer and HSIL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative predictive value of DNA methylation</measure>
    <time_frame>1 year</time_frame>
    <description>Negative predictive value of DNA methylation compared with histological results for the differentiation of cervical cancer and HSIL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation coefficient of DNA methylation with other screening methods</measure>
    <time_frame>1 year</time_frame>
    <description>Correlation coefficient of DNA methylation with high-risk HPV and TCT results</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>DNA Methylation</condition>
  <condition>Uterine Cervical Cancer</condition>
  <condition>High Grade Squamous Intraepithelial Lesions</condition>
  <condition>Low Grade Squamous Intraepithelial Lesions</condition>
  <arm_group>
    <arm_group_label>Benign group</arm_group_label>
    <description>Patients with benign cervical histology, including normal findings, inflammation and LSIL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HSIL group</arm_group_label>
    <description>Patients with cervical histology of HSIL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cancer group</arm_group_label>
    <description>Patients with cervical histology of cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>DNA methylation</intervention_name>
    <description>DNA methylation for the cervical cytology</description>
    <arm_group_label>Benign group</arm_group_label>
    <arm_group_label>Cancer group</arm_group_label>
    <arm_group_label>HSIL group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>high-risk HPV</intervention_name>
    <description>High-risk HPV testing for the cervical cytology</description>
    <arm_group_label>Benign group</arm_group_label>
    <arm_group_label>Cancer group</arm_group_label>
    <arm_group_label>HSIL group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>TCT</intervention_name>
    <description>Thin prep liquid-based cytology test for the cervical cytology</description>
    <arm_group_label>Benign group</arm_group_label>
    <arm_group_label>Cancer group</arm_group_label>
    <arm_group_label>HSIL group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        1. Wtih confirmed cervical histology within one month when collecting cervical cytology

          2. Aged 18 years or older
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed cervical histology within one month when collecting cervical cytology

          -  Aged 18 years or older

          -  Signed an approved informed consents

        Exclusion Criteria:

          -  Not meeting any of the inclusion criteria
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lei Li, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lei Li, M.D.</last_name>
    <phone>+8613911988831</phone>
    <email>lileigh@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lei Li</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Li, MD</last_name>
      <phone>008613911988831</phone>
      <email>lileigh@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 21, 2019</study_first_submitted>
  <study_first_submitted_qc>May 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2019</study_first_posted>
  <last_update_submitted>May 22, 2019</last_update_submitted>
  <last_update_submitted_qc>May 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Lei Li</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Squamous Intraepithelial Lesions of the Cervix</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

